BIOVENTUS INC - A (BVS)

US09075A1088 - Common Stock

4.48  -0.07 (-1.54%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIOVENTUS INC - A

NASDAQ:BVS (4/19/2024, 7:00:02 PM)

4.48

-0.07 (-1.54%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap354.68M
Shares
PEN/A
Fwd PE28.31
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BVS Daily chart

Company Profile

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 970 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its Pain Treatments consist of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions consist of bone graft substitutes (BGS) to fuse and grow bones and ultrasonic medical devices used for precise bone sculpting, removal of tumors, and tissue debridement in various surgeries, including spine and neurosurgery. Its Restorative Therapies consist of an ultrasonic bone healing system for fracture care, and advanced rehabilitation devices designed to help patients regain leg or hand function due to stroke.

Company Info

BIOVENTUS INC - A

4721 Emperor Boulevard, Suite 100

Durham NORTH CAROLINA 27703

P: 19194746700

CEO: Kenneth M. Reali

Employees: 970

Website: https://www.bioventus.com/

BVS News

News Imagea month ago - Bioventus, Inc.Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
News Imagea month ago - Bioventus, Inc.Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024.

News Image2 months ago - Bioventus, Inc.Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
News Image2 months ago - Bragar Eagel & SquireBIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
News Image3 months ago - Bioventus, Inc.Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
News Image3 months ago - Bioventus, Inc.Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active...

BVS Twits

Here you can normally see the latest stock twits on BVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example